Why the study?
Does angiotensin II mediate uterine vasoconstriction through alpha-stimulation in pregnant and nonpregnant ewes?
Does angiotensin II mediate uterine vasoconstriction through alpha-stimulation in pregnant and nonpregnant ewes?
Angiotensin II increases uterine vascular resistance indirectly via AT1 receptor-mediated release of an alpha-agonist rather than direct action on uterine vascular smooth muscle.
Answers are grounded in this paper and cite their sources.
Caution against clinical extrapolation in pregnancy; extends ovine models of indirect AT1-alpha vasoconstriction.
Intravenous angiotensin II (ANG II) increases uterine vascular resistance (UVR), whereas uterine intra-arterial infusions do not. Type 2 ANG II (AT(2)) receptors predominate in uterine vascular smooth muscle; this may reflect involvement of systemic type 1 ANG II (AT(1)) receptor-mediated alpha-adrenergic activation. To examine this, we compared systemic pressor and UVR responses to intravenous phenylephrine and ANG II without and with systemic or uterine alpha-receptor blockade and in the absence or presence of AT(1) receptor blockade in pregnant and nonpregnant ewes. Systemic alpha-receptor blockade inhibited phenylephrine-mediated increases in mean arterial pressure (MAP) and UVR, whereas uterine alpha-receptor blockade alone did not alter pressor responses and resulted in proportionate increases in UVR and MAP. Although neither systemic nor uterine alpha-receptor blockade affected ANG II-mediated pressor responses, UVR responses decreased >65% and also were proportionate to increases in MAP. Systemic AT(1) receptor blockade inhibited all responses to intravenous ANG II. In contrast, uterine AT(1) receptor blockade + systemic alpha-receptor blockade resulted in persistent proportionate increases in MAP and UVR. Uterine AT(2) receptor blockade had no effects. We have shown that ANG II-mediated pressor responses reflect activation of systemic vascular AT(1) receptors, whereas increases in UVR reflect AT(1) receptor-mediated release of an alpha-agonist and uterine autoregulatory responses.
No takes yet. Share an insight, caveat, or question.
Cox et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: